Elite Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 49

Elite Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Elite Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Elite Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Elite Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Elite Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Elite Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Elite Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Elite Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Elite Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Elite Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Elite Pharmaceuticals, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Elite Pharmaceuticals, Inc. Snapshot
Elite Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Elite Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Elite Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Elite Pharmaceuticals, Inc. – Pipeline Products Glance
Elite Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Elite Pharmaceuticals, Inc. – Drug Profiles
ELI-154
Product Description
Mechanism of Action
R&D Progress
ELI-216
Product Description
Mechanism of Action
R&D Progress
Oxycodone(CR)
Product Description
Mechanism of Action
R&D Progress
Elite Pharmaceuticals, Inc. – Pipeline Analysis
Elite Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Elite Pharmaceuticals, Inc. Pipeline Products By Target
Elite Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Elite Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Elite Pharmaceuticals, Inc. – Company Statement
Elite Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 01, 2010: Elite Announces Acquisition Of Generic Naltrexone Product
Sep 01, 2010: Elite Announces Acquisition Of Generic Naltrexone Product
Dec 02, 2009: Elite Phramaceutals And The Pharmanetwork Announces FDA Approval Of Generic Methadone Tablets
Sep 30, 2009: Elite Pharmaceuticals, Inc. Enters In To Agreement With The U.S. Food And Drug Administration (FDA) Under A Special Protocol Assessment (SPA) On A Phase 3 Trial Of ELI-216.
Sep 30, 2009: Elite Pharmaceuticals Inc. Receives Approval From An Independent Review Of Its Abuse Resistant Drug Product, ELI-216.
Feb 15, 2007: Elite Pharmaceuticals, Inc. Completes The First Stage Of Its Phase II study for ELI-216
Sep 12, 2006: Elite Pharmaceuticals Provides Update On Company’s Progress On ELI-154 Product
Jun 27, 2006: Elite Pharmaceuticals Successfully Concludes Second Pilot Phase I Trial Of Its Once-Daily Oxycodone Hydrochloride Product ELI-154
May 25, 2006: Elite Pharmaceuticals Enters Second Pilot Phase I Trials Of Its Once-Daily Oxycodone Product ELI-154
May 26, 2005: Elite Pharmaceuticals Announces USFDA IND Approval For ELI-216(ART) For Its Abuse-Resistant Oxycodone Product, ELI-154
Financial Deals Landscape
Elite Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Elite Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Elite Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Elite Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
Elite Pharmaceuticals Completes Private Placement Of $3.75 Million
Elite Pharmaceuticals Completes Private Placement Of $2 Million
Elite Pharmaceuticals Completes Private Placement Of Series C Convertible Preferred Stock For $15 Million
Elite Pharmaceuticals Completes Private Placement Of Series B Convertible Preferred Stock For $10 Million
Elite Pharmaceuticals Completes Private Placement Of Series A Preferred Stock For $6.6 Million
Elite Pharmaceuticals Enters Into Co-Development Agreement With ThePharmaNetwork
Elite Pharmaceuticals Enters Into Co-Development Agreement With Orit Laboratories
Elite Pharmaceuticals Enters Into Agreement With IntelliPharmaCeutics
Licensing Agreements
Elite Pharmaceuticals Enters Into Co-Development And Licensing Agreement With Pliva
Elite Pharmaceuticals Enters Into Agreement With Harris Pharmaceutical And Tish Technologies
Elite Pharmaceuticals Terminates Co-Development And Licensing Agreement With Pliva
Elite Pharmaceuticals Terminates Licensing Agreement With Harris Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Aerospace and Defence Industry - Global Strategic Business Report
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Thailand Defence and Security Report Q2 2013
• Charter Schools - Global Outlook